Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal PDE2A Primary Antibody for CM, ELISA - ABIN2747086
Netherton, Maurice: Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. in Molecular pharmacology 2005
Show all 27 Pubmed References
Human Polyclonal PDE2A Primary Antibody for ELISA, WB - ABIN562142
Bazhin, Kahnert, Kimpfler, Schadendorf, Umansky: Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. in Molecular immunology 2010
Human Monoclonal PDE2A Primary Antibody for FACS, IHC - ABIN2454150
Tanaka, Tanaka, Harada, Kohda, Matsumura, Shimamoto, Sawabe, Marunaka, Kuwabara, Takahashi, Ito, Nakahari: A PKG inhibitor increases Ca(2+)-regulated exocytosis in guinea pig antral mucous cells: cAMP accumulation via PDE2A inhibition. in American journal of physiology. Gastrointestinal and liver physiology 2013
the well-known interaction between AIP (show AIP Antibodies) and 2 different isoforms of phosphodiesterases (PDEs), PDE2A3 and PDE4A5, is of particular interest. While the interaction with over-expressed AIP (show AIP Antibodies) does not seem to affect PDE2A3 function, the reported effect on PDE4A5 is, in contrast, reduced enzymatic activity.
Lu AF33241 represents a novel PDE2A/PDE10A (show PDE10A Antibodies) inhibitor tool which can penetrate the blood brain barrier.
curcumin exerts its in vitro anti-angiogenic and in vivo anti-tumour properties through combined PDE2 and PDE4 (show PDE4A Antibodies) inhibition
PDE2A is involved in growth and invasion of human malignant melanoma PMP cells.
This study reports the X-ray crystal structure of PDE2A in complex with a highly selective, nanomolar inhibitor (BAY60-7550) at 1.9 A resolution, and the structure of apo (show C9orf3 Antibodies) PDE2 at 2.0 A resolution.
PDE2 overexpression in healthy cardiomyocytes reduces the rise in cyclic AMP (show APRT Antibodies) levels and L-type calcium current amplitude, and abolishes the inotropic effect following acute beta-adrenergic receptor stimulation.
Our results demonstrated that the PDE2A2 variant carrying point mutations is expressed in PMP cells and may affect cell cycle progression by modulating cyclin A (show CCNA2 Antibodies) expression.
the phosphodiesterase 2A isoform localized to mitochondria regulates respiration
Inhibition of PDE2 resulted in higher levels of intracellular cAMP than inhibition of PDE3A (show PDE3A Antibodies) suggesting this PDE (show ALDH7A1 Antibodies) may be the more important regulator of cAMP in human platelets.
TNF-alpha (show TNF Antibodies)-mediated up-regulation of PDE2 may destabilize endothelial barrier function in sepsis
Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by PDE2A.
Effect of PDE2 inhibition on stress-induced memory impairment is potentially mediated via modulation of neuroplasticity-related NMDAR (show GRIN1 Antibodies)-CaMKII (show CAMK2G Antibodies)-cGMP/cAMP signaling.
We conclude that increased AM PDE2A is an important negative regulator of macrophage iNOS (show NOS2 Antibodies) expression.
results demonstrate strong presynaptic inhibition by natriuretic peptides in the brain and suggest important physiological and behavioral roles of PDE2A in modulating neurotransmitter release
cGMP binding to PDE2 GAF-B activates the enzyme rapidly, stoichiometrically, and in an all or none fashion, rather than variably over a large range of cyclic nucleotide concentrations
HV(T)-induced endothelial barrier dysfunction resulted from a simultaneous increase in NO/sGC (show NPR1 Antibodies)-derived cGMP and PDE2A expression causing decreased cAMP.
Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin (show F2 Antibodies) via Rac1 and NADPH oxidase 2 (show CYBB Antibodies).
activation induces decreased cAMP accumulation\; involved in nitric oxide mediated signaling in cardiac fibroblasts
phosphodiesterase 2A, cGMP-stimulated
, cGMP-dependent 3',5'-cyclic phosphodiesterase
, phosphodiesterase 2A
, cGMP-dependent 3',5'-cyclic phosphodiesterase-like
, cGMP-stimulated phosphodiesterase 1
, cGMP-stimulated phosphodiesterase 4
, cyclic GMP-stimulated phosphodiesterase
, cyclic GMP stimulated phosphodiesterase
, c-GMP stimulated phosphodiesterase